Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma.
CD38 antigen
daratumumab
drug resistance
multiple myeloma
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
09 01 2020
09 01 2020
Historique:
received:
12
12
2019
revised:
31
12
2019
accepted:
03
01
2020
entrez:
16
1
2020
pubmed:
16
1
2020
medline:
16
1
2021
Statut:
epublish
Résumé
Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the treatment of multiple myeloma (MM). Although recent data have demonstrated very promising results in clinical practice and trials, some patients do not achieve a partial response, and ultimately all patients undergo progression. Dara exerts anti-MM activity via antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and immunomodulatory effects. Deregulation of these pleiotropic mechanisms may cause development of Dara resistance. Knowledge of this resistance may improve the therapeutic management of MM patients.
Identifiants
pubmed: 31936617
pii: cells9010167
doi: 10.3390/cells9010167
pmc: PMC7017193
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
daratumumab
4Z63YK6E0E
ADP-ribosyl Cyclase 1
EC 3.2.2.6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Références
N Engl J Med. 2018 Feb 8;378(6):518-528
pubmed: 29231133
Front Immunol. 2017 Sep 13;8:1124
pubmed: 28955340
Cells. 2019 Nov 27;8(12):
pubmed: 31783629
Cell. 1981 Mar;23(3):771-80
pubmed: 7013988
Mol Immunol. 2005 Feb;42(4):501-10
pubmed: 15607806
Br J Haematol. 2007 Sep;138(6):756-60
pubmed: 17760807
J Clin Invest. 2017 Mar 1;127(3):780-789
pubmed: 28248200
Leukemia. 2016 Mar;30(3):640-8
pubmed: 26487273
Cancer Res. 2009 Apr 1;69(7):3196-204
pubmed: 19276363
Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):728-32
pubmed: 21187373
J Clin Invest. 2002 Dec;110(12):1823-30
pubmed: 12488432
Oncologist. 2016 Nov;21(11):1355-1361
pubmed: 27486203
J Immunol. 2011 Feb 1;186(3):1840-8
pubmed: 21187443
Immunol Lett. 2018 Jul;199:16-22
pubmed: 29702148
Neoplasia. 2019 Jan;21(1):93-105
pubmed: 30529074
J Clin Med. 2019 Jul 09;8(7):
pubmed: 31323969
Cancer Microenviron. 2011 Dec;4(3):313-23
pubmed: 21866321
Cell Rep. 2018 Jun 26;23(13):3946-3959.e6
pubmed: 29949776
Front Biosci (Landmark Ed). 2014 Jan 01;19:152-62
pubmed: 24389178
Nat Rev Immunol. 2009 Oct;9(10):729-40
pubmed: 19730437
Mol Med. 2016 Dec;22:694-704
pubmed: 27761584
Cancer. 2019 Sep 1;125(17):2991-3000
pubmed: 31090928
MAbs. 2015;7(2):311-21
pubmed: 25760767
Leukemia. 2015 Feb;29(2):406-14
pubmed: 24903480
Haematologica. 2016 Aug;101(8):e339-42
pubmed: 27151995
Immunol Rev. 2001 Apr;180:177-89
pubmed: 11414360
Science. 1993 Nov 12;262(5136):1056-9
pubmed: 8235624
Leuk Lymphoma. 2018 Mar;59(3):542-561
pubmed: 28610537
Immunol Rev. 2016 Mar;270(1):95-112
pubmed: 26864107
Front Immunol. 2018 Sep 20;9:2134
pubmed: 30294326
Clin Cancer Res. 2018 Aug 15;24(16):4006-4017
pubmed: 29666301
Oncoimmunology. 2018 May 7;7(8):e1458809
pubmed: 30221054
Front Immunol. 2014 Dec 02;5:618
pubmed: 25520723
Blood. 2016 Jul 7;128(1):37-44
pubmed: 27216216
Clin Cancer Res. 2014 Sep 1;20(17):4574-83
pubmed: 24987056
N Engl J Med. 2016 Aug 25;375(8):754-66
pubmed: 27557302
Oncoimmunology. 2013 Sep 1;2(9):e26246
pubmed: 24319640
Clin Cancer Res. 2014 Feb 15;20(4):847-58
pubmed: 24297864
Lancet. 2016 Apr 9;387(10027):1551-1560
pubmed: 26778538
Cancer Res. 2015 Oct 1;75(19):4074-85
pubmed: 26294209
Oncoimmunology. 2017 Oct 31;7(2):e1386361
pubmed: 29308308
Oncotarget. 2018 Apr 17;9(29):20563-20577
pubmed: 29755672
Front Immunol. 2012 Nov 09;3:335
pubmed: 23162553
Lancet. 2019 Jul 6;394(10192):29-38
pubmed: 31171419
Immunol Lett. 2019 Jan;205:40-50
pubmed: 30447309
Blood. 2018 Jan 4;131(1):13-29
pubmed: 29118010
Transl Oncol. 2018 Dec;11(6):1350-1357
pubmed: 30196237
Cancer Res. 2011 Mar 15;71(6):2298-307
pubmed: 21252115
Expert Rev Clin Immunol. 2018 Mar;14(3):197-206
pubmed: 29465271
Cell Mol Immunol. 2011 Mar;8(2):157-63
pubmed: 21258360
Ann N Y Acad Sci. 2016 Jan;1364:32-51
pubmed: 27002787
MAbs. 2014;6(5):1133-44
pubmed: 25517299
Curr Top Microbiol Immunol. 2014;382:373-92
pubmed: 25116109
Leukemia. 2013 Apr;27(5):1177-81
pubmed: 22955446
Blood Rev. 2018 Nov;32(6):480-489
pubmed: 29709247
Nat Immunol. 2003 Sep;4(9):815
pubmed: 12942076
Immunity. 2006 Jan;24(1):19-28
pubmed: 16413920
J Immunol. 2014 Mar 1;192(5):2252-60
pubmed: 24489098
Mol Med. 2013 May 20;19:99-108
pubmed: 23615966
Expert Opin Biol Ther. 2017 Jul;17(7):887-893
pubmed: 28434255
Immunol Today. 1994 Mar;15(3):95-7
pubmed: 8172650
Leukemia. 2016 Feb;30(2):399-408
pubmed: 26338273
Blood Adv. 2017 Oct 24;1(23):2105-2114
pubmed: 29296857
Cancer Discov. 2018 Sep;8(9):1156-1175
pubmed: 30012853
Sci Transl Med. 2013 Feb 20;5(173):173ra23
pubmed: 23427243
Blood Cancer J. 2018 Jan 12;8(1):7
pubmed: 29330358
Leukemia. 2014 Apr;28(4):904-16
pubmed: 23995611
Clin Cancer Res. 2017 Dec 15;23(24):7498-7511
pubmed: 29025767
Cells. 2015 Sep 17;4(3):520-37
pubmed: 26393653
Oncotarget. 2016 Sep 13;7(37):60698-60711
pubmed: 27474171
N Engl J Med. 2016 Oct 6;375(14):1319-1331
pubmed: 27705267
Leukemia. 2015 Oct;29(10):2039-49
pubmed: 25975191
Blood. 2016 Aug 18;128(7):959-70
pubmed: 27307294
J Immunol. 1998 Mar 1;160(5):2238-47
pubmed: 9498763
Front Immunol. 2017 Mar 20;8:280
pubmed: 28373871
Mol Pharmacol. 2014 Nov;86(5):485-91
pubmed: 24944188
Blood. 2016 Jul 21;128(3):384-94
pubmed: 27222480
Trends Cell Biol. 2009 Feb;19(2):72-80
pubmed: 19144521